Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

  1. De Laurentiis, M.
  2. Borstnar, S.
  3. Campone, M.
  4. Warner, E.
  5. Bofill, J.S.
  6. Jacot, W.
  7. Dent, S.
  8. Martin, M.
  9. Ring, A.
  10. Cottu, P.
  11. Lu, J.
  12. Ciruelos, E.
  13. Azim, H.A.
  14. Chatterjee, S.
  15. Zhou, K.
  16. Wu, J.
  17. Menon-Singh, L.
  18. Zamagni, C.
Revista:
Breast Cancer Research and Treatment

ISSN: 1573-7217,  0167-6806

Any de publicació: 2021

Volum: 189

Número: 3

Pàgines: 689-699

Tipus: Article

DOI: 10.1007/S10549-021-06334-0 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus